REFERENCES
- Hajjar FM, Pearson HA. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr. 1994;125:490–492.
- Taher A, Isma’eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006;37:12–20.
- Yavarian M, Karimi M, Bakker E, Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. Haematologica. 2004;89:1172–1178.
- Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
- Mahboudi F, Zeinali S, Merat A, The molecular basis of β-thalassemia mutations in Fars Province, Iran. Irn J Med Sci. 1996;21:99–104.
- Najmabadi H, Karimi-Nejad R, Sahebjam S, The beta-thalassemia mutation spectrum in the Iranian population. Hemoglobin. 2001;25:285–296.
- Nozari G, Rahbar S, Golshaiyzan A, Molecular analyses of beta-thalassemia in Iran. Hemoglobin. 1995;19:425–431.
- Najmabadi H, Teimourian S, Khatibi T, Amplification refractory mutation system (ARMS) and reverse hybridization in the detection of β-thalassemia mutations. Arch Iran Med. 2001;4:165–170.
- Eshghi P, Zadeh-Vakili A, Rashidi A, An unusually frequent β-thalassemia mutation in an Iranian province. Hemoglobin. 2008;32:387–392.
- Eshghi P, Rashidi A, Zadeh-Vakili A, Hematological phenotype of the IVS-I-5 (G-C) beta-thalaeesemia mutation and assessment of Iran's national criteria. Hemoglobin. 2008;32:440–445.
- Sutton M, Bouhassira EE, Nagel RL. Polymerase chain reaction amplification applied to the determination of beta-like globin gene cluster haplotypes. Am J Hematol. 1989;32:66–69.
- Hoppe C, Vichinsky E, Lewis B, Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. Am J Hematol. 1999;62:221–227.
- Bradai M, Pissard S, Abad MT, Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion. 2007;47:1830–1836.
- Chakrabarti P, Gupta R, Mishra A, Spectrum of beta-thalassemia mutations in North Indian states: a β-thalassemia trait with two mutations in cis. Clin Biochem. 2005;38:576–578.
- Neishabury M, Azarkeivan A, Oberkanins C, Molecular mechanisms underlying thalassemia intermedia in Iran. Genet Test. 2008;12:549–556.
- Koren A, Levin C, Dgany O, Response to hydroxyurea therapy in beta-thalassemia. Am J Hematol. 2008;83:366–370.
- Dixit A, Chatterjee TC, Mishra P, Hydroxyurea in thalassemia intermedia—a promising therapy. Ann Hematol. 2005;84:441–446.
- Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27:380–385.
- Khan SN, Riazuddin S. Molecular characterization of beta-thalassemia in Pakistan. Hemoglobin. 1998;22:333–345.
- Khateeb B, Moatter T, Shaghil AM, Genetic diversity of beta-thalassemia mutations in Pakistani population. J Pak Med Assoc. 2000;50:293–296.
- Baig SM, Azhar A, Hassan H, Spectrum of beta-thalassemia mutations in various regions of Punjab and Islamabad, Pakistan: establishment of prenatal diagnosis. Haematologica. 2006;91:ELT02.